TriSalus Life Sciences (TLSI) Share-based Compensation (2022 - 2026)

TriSalus Life Sciences has reported Share-based Compensation for 5 years, with the latest figure at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 52.59% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $10.0 million (up 67.08% YoY), and the FY2025 full-year result was $9.1 million, up 67.82% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.5 million, up from $2.2 million in the prior quarter.
• The five-year high for Share-based Compensation was $3.4 million in Q3 2025, with the low at $68000.0 in Q2 2023.
• Historically, Share-based Compensation has averaged $1.3 million across 5 years, with a median of $1.3 million in 2024.
• Annual changes were most pronounced in 2024 — Share-based Compensation jumped 1775.0% — and 2025, when it climbed 29.46%.
• TriSalus Life Sciences' Share-based Compensation stood at $117000.0 in 2022, then soared by 754.7% to $1.0 million in 2023, then surged by 69.7% to $1.7 million in 2024, then advanced by 29.46% to $2.2 million in 2025, then advanced by 12.52% to $2.5 million in 2026.
• The last three Share-based Compensation figures came in at $2.5 million (Q1 2026), $2.2 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.